Rong Chen, PhD Email Rong Chen
- ASSISTANT PROFESSOR | Genetics and Genomic Sciences
Dr. Chen's research focuses on developing databases, genome repositories, and clinical applications to interpret personal genomes for clinical diagnosis, precision medicine, predictive disease risk, and novel therapeutics.
Prior to Mount Sinai, he led the collaborative efforts at Stanford University to drive personalized medicine and clinical diagnosis on Mendelian and complex diseases using genome and exome sequencing. Dr. Chen also helped launch a startup company Personalis, which won the VA's contract for the Million Veteran Genome project.
Dr. Chen has a broad interest in translational bioinformatics and genome interpretation, and has published over 60 papers in Lancet, Cell, Nature Biotechnology, Nature Methods, PNAS, AJHG, PLoS Genetics, PLoS Computational Biology, Genome Research, Genome Biology, Genome Medicine, AJT, and Proteins. He holds numerous patents for software and databases on personalized medicine, diagnosis, and structure modeling.
Bioinformatics, Cancer, Genetics, Genomics, Systems Biology, Transplantation
Multi-Disciplinary Training Areas
Cancer Biology [CAB], Immunology [IMM], Microbiology [MIC], Neuroscience [NEU], Pharmacology and Therapeutics Discovery [PTD]
BS, University of Science and Technology of China
MS, Shanghai Institute of Organic Chemistry
PhD, Boston University
ICHG Young Investigator Awards
International Congress of Human Genetics
My research focuses on translational bioinformatics and genome interpretation. We have been building hundreds of databases from mining literature and public repositories, and integrating genomic, genetic, phenotypic, clinical, and environmental data to illustrate disease mechanisms, identify diagnostics biomarkers, and drive personalized medicine. For more about informatics, please check Chen Laboratory.
To view a complete list of publications, please click here.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Chen during 2020 and/or 2021. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)
Other activities: Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.